Journal of Metabolic Syndrome

Introduction: Several studies have investigated the impact of male obesity on the traditional sperm parameters but it is unclear if in the male obesity, accessory glands secretory function may be altered. In this paper the seminal parameters and the biochemical markers of accessory sex glands are related with the Body Mass Index (BMI).

Material and methods: 1148 patients attending a Fertility Center with subfertility were included in the study. Weight and height were recorded to calculate BMI in each patient. Semen parameters and markers of male accessory glands were measured. Pearson´s correlation coefficient has been performed, p-values below 0.01 were considered statistically significant.

Results: In HOS tests a reduction was observed in I and II-III obesity groups, sperm /ejaculate number, seminal volume and citric acid decrease were correlated inversely with the body mass index. Seminal fructose levels tend to increase in proportion to body mass. The correlation analysis in all the individuals indicates a trend for increase in BMI over time.

Conclusion: Obesity has a negative impact on sperm quality and prostatic function, although sperm parameters changes are more evident in men with morbid obesity. Oxidative stress, hormonal and metabolic changes increase as adiposity progresses in an individual, so we may expect infertility, prostate pathologies could be avoided if hyperadiposity in infertile men is controlled opportunely.

Risk factors that define the metabolic syndrome (MetS) develop with age increasing its prevalence. Therefore, MetS can be considered an age-related health problem. Mechanism involved in aging and MetS are incompletely understood. The goal of this review is to highlight novel molecular maladaptive mechanism that tiger cardiac disease and common in aging and MetS. We focus on mitochondrial energetic function as well as mitochondrial calcium handling. In addition, we analyzed the role of O-GlcNAcylation which is a posttranslational modification that triggers multiple signaling pathways.

Diabetes Mellitus (DM) is an old disease (Diabetes) in China (over two thousand years) but modern epidemics in western medicines (approximately 100 years). Despite some DM treatment advances, causality, pathogenesis and therapeutics of diabetes is currently too complicated to be easily managed in the clinic. Disease complications (cardiovascular symptoms, vision impairments, nephropathies, chronic leg infections and so on) are more fatal than anti-diabetic control. More importantly, different doctors and pharmaceutical companies often hold different views on DM treatments. To systematically compare between different forms of anti-diabetic therapeutics, new ideas, drug development pipelines, experimental/clinical model establishments and possible future directions are highlighted in this mini-review.